Giulia Caron

University of Turin

Italy

Research Interests

Explore related searches

Professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Mauro Ravera

Full Professor of General and Inorganic Chemistry

Università degli Studi del Piemonte Orientale

ITALY

View details

Giuseppe Ermondi

University of Turin

ITALY

View details

Paola Petrini

Professore Associato / Associate Professor

Politecnico di Milano

ITALY

View details

Jan Kihlberg

Professor

Uppsala University

SWEDEN

View details

Matteo Rossi Sebastiano

University of Turin

ITALY

View details

Elisabetta Gabano

Università degli Studi del Piemonte Orientale

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Giulia Caron

Research Interests

Explore related searches

Contact this professor

Articles (16)

Linker Methylation as a Strategy to Enhance PROTAC Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis

Macrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors

Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders

Molecular properties, including chameleonicity, as essential tools for designing the next generation of oral beyond rule of five drugs

IMHB-Mediated Chameleonicity in Drug Design: A Focus on Structurally Related PROTACs

DegraderTCM: A Computationally Sparing Approach for Predicting Ternary Degradation Complexes

Chamelogk: A Chromatographic Chameleonicity Quantifier to Design Orally Bioavailable Beyond-Rule-of-5 Drugs

The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline

Cystic Fibrosis Mucus Model to Design More Efficient Drug Therapies

Application of the anthraquinone drug rhein as an axial ligand in bifunctional Pt(iv) complexes to obtain antiproliferative agents against human glioblastoma cells

Refinement of Computational Access to Molecular Physicochemical Properties: From Ro5 to bRo5

Designing Soluble PROTACs: Strategies and Preliminary Guidelines

Steering New Drug Discovery Campaigns: Permeability, Solubility, and Physicochemical Properties in the bRo5 Chemical Space

Managing Experimental 3D Structures in the Beyond‐Rule‐of‐5 Chemical Space: The Case of Rifampicin

Rational Control of Molecular Properties Is Mandatory to Exploit the Potential of PROTACs as Oral Drugs

Pt(iv) complexes based on cyclohexanediamines and the histone deacetylase inhibitor 2-(2-propynyl)octanoic acid: synthesis, characterization, cell penetration properties and antitumor activity

Collaborators (6)

Mauro Ravera

Giuseppe Ermondi

Paola Petrini

Jan Kihlberg

Matteo Rossi Sebastiano

Elisabetta Gabano

Make your next move.